BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/31/2024 7:03:00 AM | Browse: 467 | Download: 953
Publication Name World Journal of Gastroenterology
Manuscript ID 89460
Country Italy
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Letter to the Editor
Article Title Prevention of hepatitis B reactivation in patients with hematologic malignancies treated with novel systemic therapies: Who and Why?
Manuscript Source Unsolicited Manuscript
All Author List Matteo Tonnini, Clara Solera Horna and Luca Ielasi
ORCID
Author(s) ORCID Number
Luca Ielasi http://orcid.org/0000-0003-4162-2319
Funding Agency and Grant Number
Corresponding Author Luca Ielasi, MD, Doctor, Doctor, Department of Internal Medicine, Ospedale degli Infermi di Faenza, Viale Stradone, 9, Faenza 48018, Italy. luca.ielasi.kr@gmail.com
Key Words Hepatitis B reactivation; Hepatitis B virus; Antiviral prophylaxis; Hematologic malignancies; Chimeric antigens receptor-T cell therapy; Immune checkpoint inhibitors
Core Tip In the last few years, the advent of several new therapies has characterized the therapeutic scenario of hematologic malignancies. There is now the open issue of assessing the risk of hepatitis B virus reactivation in these patients in order to decide which patients should undergo antiviral prophylaxis.
Publish Date 2024-01-31 07:03
Citation Tonnini M, Solera Horna C, Ielasi L. Prevention of hepatitis B reactivation in patients with hematologic malignancies treated with novel systemic therapies: Who and Why? World J Gastroenterol 2024; 30(5): 509-511
URL https://www.wjgnet.com/1007-9327/full/v30/i5/509.htm
DOI https://dx.doi.org/10.3748/wjg.v30.i5.509
Full Article (PDF) WJG-30-509-with-cover.pdf
Full Article (Word) WJG-30-509.docx